CVR number 28962630
Industry 86.9040 Other human health activities

KIROPRAKTISK KLINIK KGS. LYNGBY ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Bankruptcy risk for industry  0.6% 0.6% 0.6% 0.6% 0.6%  
Bankruptcy risk  2.0% 10.4% 2.8% 2.1% 1.5%  
Credit score (0-100)  70 23 58 66 75  
Credit rating  A BB BBB BBB A  
Credit limit (kDKK)  0.7 0.0 0.0 0.3 23.9  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Gross profit  843 788 870 820 917  
EBITDA  603 261 315 207 301  
EBIT  459 261 315 207 301  
Pre-tax profit (PTP)  612.1 401.7 -156.3 439.4 731.4  
Net earnings  474.7 313.4 -157.1 377.1 570.5  
Pre-tax profit without non-rec. items  612 402 -156 439 731  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  5,204 5,407 5,136 5,400 5,855  
Interest-bearing liabilities  482 781 336 391 286  
Balance sheet total (assets)  6,068 6,429 5,651 5,879 6,365  
Net Debt  -3,515 -5,645 -1,598 -1,717 -1,971  
 
See the entire balance sheet

Volume 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  843 788 870 820 917  
Gross profit growth  2.0% -6.5% 10.4% -5.7% 11.9%  
Employees  0 0 0 0 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  6,068 6,429 5,651 5,879 6,365  
Balance sheet change%  6.9% 5.9% -12.1% 4.0% 8.3%  
Added value  603.1 261.5 315.4 207.3 300.9  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -144 0 255 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  54.5% 33.2% 36.3% 25.3% 32.8%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  11.0% 7.0% 7.5% 7.6% 11.9%  
ROI %  11.8% 7.4% 7.8% 7.8% 12.3%  
ROE %  9.5% 5.9% -3.0% 7.2% 10.1%  

Solidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Equity ratio %  85.8% 84.1% 90.9% 91.8% 92.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -582.9% -2,158.8% -506.6% -828.5% -655.2%  
Gearing %  9.3% 14.5% 6.5% 7.2% 4.9%  
Net interest  0 0 0 0 0  
Financing costs %  7.0% 5.8% 109.4% 0.1% 0.0%  

Liquidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Quick Ratio  6.0 10.3 10.8 22.2 9.8  
Current Ratio  6.0 10.3 10.8 22.2 9.8  
Cash and cash equivalent  3,997.8 6,425.9 1,933.5 2,107.9 2,257.3  

Capital use efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  3,129.1 5,724.3 1,784.8 2,040.0 2,026.6  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 301  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 301  
EBIT / employee  0 0 0 0 301  
Net earnings / employee  0 0 0 0 571